Get a grip on immune cells by inhibiting JAKs
| Autor: | Dominik Wolf, Janna Rudolph, Sowmya Parampalli Yajnanarayana, Kathrin Schönberg |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
business.industry Immunology Inflammation Disease medicine.disease medicine.disease_cause Autoimmunity 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Immune system Polycythemia vera Oncology 030220 oncology & carcinogenesis hemic and lymphatic diseases medicine Immunology and Allergy medicine.symptom Myelofibrosis business Author's View Disease burden |
| Zdroj: | Oncoimmunology. 5(2) |
| ISSN: | 2162-4011 |
| Popis: | JAK inhibitors are approved for myelofibrosis (MF) and polycythemia vera (PV), as they reverse inflammation-associated splenomegaly and symptoms. Notably, JAK inhibitors only marginally affect disease burden. The anti-inflammatory effects of JAK inhibitors affects DC, T and NK cells explaining their therapeutic potential for limitation of cancer-associated inflammation, Graft-versus-Host Disease (GvHD) and autoimmunity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|